PL3141552T3 - Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej - Google Patents
Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowejInfo
- Publication number
- PL3141552T3 PL3141552T3 PL16190699T PL16190699T PL3141552T3 PL 3141552 T3 PL3141552 T3 PL 3141552T3 PL 16190699 T PL16190699 T PL 16190699T PL 16190699 T PL16190699 T PL 16190699T PL 3141552 T3 PL3141552 T3 PL 3141552T3
- Authority
- PL
- Poland
- Prior art keywords
- protein kinase
- inhibitory activity
- thienopyrimidine derivatives
- thienopyrimidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20100008720A KR101483215B1 (ko) | 2010-01-29 | 2010-01-29 | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 |
| PCT/KR2011/000615 WO2011093672A2 (en) | 2010-01-29 | 2011-01-28 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase |
| EP16190699.5A EP3141552B1 (en) | 2010-01-29 | 2011-01-28 | Thienopyrimidine derivatives having inhibitory activity for protein kinase |
| EP11737311.8A EP2528920A4 (en) | 2010-01-29 | 2011-01-28 | BICYCLIC HETEROARYL DERIVATIVES WITH HEMMETIC EFFECT ON PROTEIN KINASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3141552T3 true PL3141552T3 (pl) | 2019-08-30 |
Family
ID=44320004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16190699T PL3141552T3 (pl) | 2010-01-29 | 2011-01-28 | Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10112954B2 (pl) |
| EP (2) | EP3141552B1 (pl) |
| JP (1) | JP5844284B2 (pl) |
| KR (1) | KR101483215B1 (pl) |
| CN (1) | CN102741256B (pl) |
| ES (1) | ES2726882T3 (pl) |
| PL (1) | PL3141552T3 (pl) |
| TR (1) | TR201906936T4 (pl) |
| WO (1) | WO2011093672A2 (pl) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101347303B1 (ko) * | 2010-01-29 | 2014-01-06 | 한미사이언스 주식회사 | 단백질 키나아제 저해활성을 갖는 티에노[3,2-ｄ]피리미딘 유도체 |
| ME03376B (me) | 2010-05-20 | 2020-01-20 | Array Biopharma Inc | Makrociklička jedinjenja kао inhibiтori trk kinaze |
| CN110003219A (zh) * | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| PH12013502020A1 (en) * | 2011-04-05 | 2018-04-11 | Pfizer Ltd | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases |
| KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
| BR112014015720B1 (pt) * | 2011-12-30 | 2020-03-17 | Hanmi Pharm. Co., Ltd. | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase |
| EP2802590B1 (en) | 2012-01-10 | 2017-03-01 | F. Hoffmann-La Roche AG | Thienopyrimidine compounds |
| MY171055A (en) * | 2012-01-19 | 2019-09-23 | Taiho Pharmaceutical Co Ltd | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| KR101582852B1 (ko) | 2012-05-24 | 2016-01-07 | 서울대학교 산학협력단 | 타우 단백질 매개 신경 퇴행성 질환 치료제 |
| RS58514B1 (sr) | 2012-06-13 | 2019-04-30 | Incyte Holdings Corp | Supstituisana triciklična jedinjenja kao inhibitori fgfr |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤 |
| CN103848823A (zh) * | 2012-12-06 | 2014-06-11 | 韩冰 | 一类治疗神经退行性疾病的化合物及其用途 |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| PH12015502383B1 (en) | 2013-04-19 | 2023-02-03 | Incyte Holdings Corp | Bicyclic heterocycles as fgfr inhibitors |
| WO2014196793A1 (en) | 2013-06-05 | 2014-12-11 | C&C Research Laboratories | Heterocyclic derivatives and use thereof |
| AU2014291161B2 (en) * | 2013-07-18 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of FGFR inhibitor |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| RS58361B1 (sr) * | 2013-07-31 | 2019-03-29 | Merck Patent Gmbh | Piridini, pirimidini i pirazini, kao inhibitori btk i njihova upotreba |
| EP3097095A1 (en) * | 2014-01-24 | 2016-11-30 | AbbVie Inc. | Furo-3-carboxamide derivatives and methods of use |
| WO2015162515A1 (en) | 2014-04-25 | 2015-10-29 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine d1 ligands |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| TWI712601B (zh) | 2015-02-20 | 2020-12-11 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
| PT3279202T (pt) | 2015-03-31 | 2020-08-31 | Taiho Pharmaceutical Co Ltd | Cristal de composto de alquinilo de benzeno 3,5-dissubstituído |
| BR112018000808A2 (pt) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | compostos de pirazolo[1,5-a]piridina substituída como inibidores de ret cinase |
| CN108348519A (zh) * | 2015-07-20 | 2018-07-31 | 台北医学大学 | 经氯苯取代的氮杂芳基化合物 |
| US10208024B2 (en) | 2015-10-23 | 2019-02-19 | Array Biopharma Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| TWI752098B (zh) | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| TWI876442B (zh) | 2017-10-10 | 2025-03-11 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| MX2020005563A (es) | 2017-11-30 | 2020-10-28 | Hanmi Pharm Ind Co Ltd | Compuesto de tieno[3,2-d]pirimidina que tiene actividad inhibidora para proteina cinasa. |
| CN107973727B (zh) * | 2017-12-11 | 2020-04-17 | 中山大学 | 间二取代苯酚化合物及其制备方法与抗结核菌应用 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| US11472802B2 (en) | 2018-01-18 | 2022-10-18 | Array Biopharma Inc. | Substituted pyrazolyl[4,3-c]pyridine compounds as RET kinase inhibitors |
| JP6918204B2 (ja) | 2018-03-19 | 2021-08-11 | 大鵬薬品工業株式会社 | アルキル硫酸ナトリウムを含む医薬組成物 |
| HRP20241288T1 (hr) | 2018-05-04 | 2024-12-06 | Incyte Corporation | Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju |
| AU2019262579B2 (en) | 2018-05-04 | 2024-09-12 | Incyte Corporation | Salts of an FGFR inhibitor |
| CN112996794A (zh) | 2018-09-10 | 2021-06-18 | 阿雷生物药品公司 | 作为ret激酶抑制剂的稠合杂环化合物 |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN112110937B (zh) * | 2019-06-20 | 2022-03-22 | 四川大学 | 一种噻吩并[2,3-d]嘧啶-4(3h)-酮衍生物及其制备方法和用途 |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3157361A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| JP7832891B2 (ja) | 2019-12-04 | 2026-03-18 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤の誘導体 |
| WO2021138392A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Aminopyrimidine compounds |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP4008716A1 (en) * | 2020-12-04 | 2022-06-08 | Martin-Luther-Universität Halle-Wittenberg | Novel inhibitors of insulin-like growth factor 2 mrna binding proteins |
| KR20230152654A (ko) | 2020-12-30 | 2023-11-03 | 타이라 바이오사이언시스, 인크. | 키나아제 억제제로서의 인다졸 화합물 |
| TW202246243A (zh) | 2021-02-26 | 2022-12-01 | 美商泰拉生物科學公司 | 胺基嘧啶化合物及其使用方法 |
| WO2022221170A1 (en) | 2021-04-12 | 2022-10-20 | Incyte Corporation | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| US11939331B2 (en) | 2021-06-09 | 2024-03-26 | Incyte Corporation | Tricyclic heterocycles as FGFR inhibitors |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| CN114524826A (zh) * | 2022-02-18 | 2022-05-24 | 郑州猫眼农业科技有限公司 | 7-溴-4-氯噻吩并[3,2-d]嘧啶的制备工艺 |
| TW202408493A (zh) | 2022-06-29 | 2024-03-01 | 美商泰拉生物科學公司 | 多晶形化合物及其用途 |
| IL317558A (en) | 2022-06-29 | 2025-02-01 | Tyra Biosciences Inc | Indazole compounds |
| WO2024138112A1 (en) | 2022-12-22 | 2024-06-27 | Tyra Biosciences, Inc. | Indazole compounds |
| TW202535368A (zh) | 2023-12-15 | 2025-09-16 | 美商泰拉生物科學公司 | 吲唑化合物 |
| WO2025222097A1 (en) | 2024-04-19 | 2025-10-23 | Tyra Biosciences, Inc. | Indazole-based protac degraders and their anticancer activity |
| WO2026035809A1 (en) | 2024-08-06 | 2026-02-12 | Tyra Biosciences, Inc. | Indazole compounds for the treatment of cancer |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| US6281227B1 (en) * | 1996-12-13 | 2001-08-28 | Aventis Pharma Deutschland Gmbh | Sulfonic acid sulfonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds |
| GB9906566D0 (en) * | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| RU2004135386A (ru) * | 2002-05-06 | 2005-07-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Тиадиазолы или оксадиазолы и их применение в качестве ингибиторов протеинкиназы jak |
| ES2351624T3 (es) * | 2003-05-06 | 2011-02-08 | Ústav Experimentálni Botaniky Av Cr, V.V.I. (Institute Of Experimental Botany Academy Of Sciences Of The Czech Republic, Pro) | Pirazolo[4,3-d]pirimidinas, procedimiento para su preparación y uso. |
| CA2565599C (en) * | 2004-05-18 | 2012-07-31 | Schering Corporation | Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors |
| JP4842929B2 (ja) | 2004-05-27 | 2011-12-21 | ファイザー・プロダクツ・インク | 癌治療に有用なピロロピリミジン誘導体 |
| US20060004002A1 (en) * | 2004-07-02 | 2006-01-05 | Thomas Thrash | Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors |
| US7514463B2 (en) * | 2004-08-20 | 2009-04-07 | University Of Kansas | Lonidamine analogues and their use in male contraception and cancer treatment |
| AU2005323797B2 (en) * | 2005-01-10 | 2009-07-09 | Pfizer Inc. | Pyrrolopyrazoles, potent kinase inhibitors |
| WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| JP2009532375A (ja) | 2006-03-30 | 2009-09-10 | タケダ サン ディエゴ インコーポレイテッド | キナーゼ阻害剤 |
| CA2651898A1 (en) * | 2006-04-07 | 2007-10-18 | Develogen Aktiengesellschaft | Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions |
| WO2008082839A2 (en) * | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| WO2009013545A2 (en) * | 2007-07-26 | 2009-01-29 | Astrazeneca Ab | Chemical compounds |
| CN102712646A (zh) | 2009-08-28 | 2012-10-03 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| CN110003219A (zh) * | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
-
2010
- 2010-01-29 KR KR20100008720A patent/KR101483215B1/ko active Active
-
2011
- 2011-01-28 PL PL16190699T patent/PL3141552T3/pl unknown
- 2011-01-28 TR TR2019/06936T patent/TR201906936T4/tr unknown
- 2011-01-28 WO PCT/KR2011/000615 patent/WO2011093672A2/en not_active Ceased
- 2011-01-28 JP JP2012551091A patent/JP5844284B2/ja active Active
- 2011-01-28 EP EP16190699.5A patent/EP3141552B1/en active Active
- 2011-01-28 CN CN201180007509.3A patent/CN102741256B/zh active Active
- 2011-01-28 EP EP11737311.8A patent/EP2528920A4/en not_active Withdrawn
- 2011-01-28 ES ES16190699T patent/ES2726882T3/es active Active
- 2011-01-28 US US13/575,799 patent/US10112954B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TR201906936T4 (tr) | 2019-06-21 |
| US10112954B2 (en) | 2018-10-30 |
| EP2528920A2 (en) | 2012-12-05 |
| ES2726882T3 (es) | 2019-10-10 |
| US20120302567A1 (en) | 2012-11-29 |
| JP2013518098A (ja) | 2013-05-20 |
| EP3141552B1 (en) | 2019-04-17 |
| KR20110088960A (ko) | 2011-08-04 |
| CN102741256A (zh) | 2012-10-17 |
| WO2011093672A3 (en) | 2012-01-05 |
| EP2528920A4 (en) | 2013-08-07 |
| KR101483215B1 (ko) | 2015-01-16 |
| JP5844284B2 (ja) | 2016-01-13 |
| CN102741256B (zh) | 2015-12-02 |
| WO2011093672A2 (en) | 2011-08-04 |
| EP3141552A1 (en) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3141552T3 (pl) | Pochodne tienopiryimidyny wykazujące aktywność hamującą względem kinazy białkowej | |
| EP2710018B8 (en) | Macrocyclic compounds as protein kinase inhibitors | |
| EP3409278B8 (en) | Heterocyclic protein kinase inhibitors | |
| ZA201405583B (en) | Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases | |
| ZA201402164B (en) | Protein kinase inhibitors | |
| IL247405A0 (en) | Apoptosis signal-regulating kinase inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| PT2531501E (pt) | Inibidores da cinase de regulação do sinal de apoptose 1 | |
| ZA201306855B (en) | Protein kinase inhibitors | |
| IL228103A0 (en) | Amino-quinolines as kinase inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| HU0900798D0 (en) | 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity | |
| IL230504A0 (en) | Selective protein kinase inhibitors | |
| EP2571884A4 (en) | SELECTIVE MTOR KINASE HEMMER | |
| EP2870158A4 (en) | PROTEIN KINASE INHIBITORS | |
| GB201109094D0 (en) | Indexable insert | |
| EP2855484A4 (en) | PROTEIN KINASE INHIBITORS | |
| EP2895166A4 (en) | AMINOISOQUINOLINE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | |
| EP2838531A4 (en) | INDOLIN-2-ONE DERIVATIVES AS INHIBITORS OF PROTEIN KINASES | |
| IL221065A (en) | General antiviral peptides for protein kinase inhibition | |
| PL2646448T3 (pl) | Makrocykliczne inhibitory kinazy | |
| HK1195057A (en) | Protein kinase inhibitors | |
| AU2012905607A0 (en) | Protein Inhibition |